A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma

Sarcoma

Volumn 2013, Issue , 2013, Pages

  Maki, Robert G ^a,b   Jungbluth, Achim A ^c   Gnjatic, Sacha ^c   Schwartz, Gary K ^a   D'Adamo, David R ^a,d   Keohan, Mary Louise ^a   Wagner, Michael J ^b   Scheu, Kelly ^a,e   Chiu, Rita ^c   Ritter, Erika ^c   Kachel, Jennifer ^a   Lowy, Israel ^f,g,h   Old, Lloyd J ^c   Ritter, Gerd ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f MEDAREX INC   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN; IPILIMUMAB; NY ESO 1 ANTIGEN;

ABDOMINAL PAIN; ACNE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHITIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; FATIGUE; FEMALE; GASTRITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IMMUNE RESPONSE; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MUSCULOSKELETAL CHEST PAIN; NAUSEA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PLEURA EFFUSION; PRIORITY JOURNAL; PROCTALGIA; RASH; SIDE EFFECT; SYNOVIAL SARCOMA; THORAX PAIN; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84876576574     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2013/168145     Document Type: Article

References (40)

1. Howlader N., Noone A. M., Krapcho M., Neyman N., Aminou R., Altekruse S. F., Kosary C. L., Ruhl J., Tatalovich Z., Cho H., Mariotto A., Eisner M. P., Lewis D. R., Chen H. S., Feuer E. J., Cronin K. A., SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) 2012 Bethesda, MD, USA National Cancer Institute. http://seer.cancer.gov/csr/1975-2009-pops09/
2. Spillane A. J., A'Hern R., Judson I. R., Fisher C., Thomas J. M., Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. Journal of Clinical Oncology 2000 18 22 3794 3803 2-s2.0-0034669290
3. De Leeuw B., Balemans M., Weghuis D. O., Seruca R., Janz M., Geraghty M. T., Gilgenkrantz S., Ropers H. H., Geurts van Kessel A., Molecular cloning of the synovial sarcoma-specific translocation (X;18)(p11.2;q11.2) breakpoint. Human Molecular Genetics 1994 3 5 745 749 2-s2.0-0028350595 (Pubitemid 24148619)
4. Clark J., Rocques P. J., Crew A. J., Gill S., Shipley J., Chan A. M. L., Gusterson B. A., Cooper C. S., Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genetics 1994 7 4 502 508 2-s2.0-0027933151 10.1038/ng0894-502 (Pubitemid 24308337)
5. Dimitriadis E., Rontogianni D., Kyriazoglou A., Takou A., Frangia K., Pandis N., Trangas T., Novel SYT-SSX fusion transcript variants in synovial sarcoma. Cancer Genetics and Cytogenetics 2009 195 1 54 58 2-s2.0-70349941254 10.1016/j.cancergencyto.2009.06.012
6. dos Santos N. R., de Bruijm D. R. H., van Kessel A. G., Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 2001 30 1 14
7. Chrysostomou A., Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001 20 40 5755 5762 2-s2.0-0035839882 10.1038/sj.onc.1204601 (Pubitemid 32928113)
8. Przybyl J., Jurkowska M., Rutkowski P., Debiec-Rychter M., Siedlecki J. A., Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. Sarcoma 2012 2012 13 249219 10.1155/2012/249219
9. Al-Hussaini H., Hogg D., Blackstein M. E., Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011 2011 7 231789 10.1155/2011/231789
10. Lewis J. J., Antonescu C. R., Leung D. H. Y., Blumberg D., Healy J. H., Woodruff J. M., Brennan M. F., Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. Journal of Clinical Oncology 2000 18 2087 2094 (Pubitemid 30324362)
11. Eilber F. C., Brennan M. F., Eilber F. R., Eckardt J. J., Grobmyer S. R., Riedel E., Forscher C., Maki R. G., Singer S., Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Annals of Surgery 2007 246 1 105 113 2-s2.0-34347361682 10.1097/01.sla. 0000262787.88639.2b (Pubitemid 47012214)
12. Edmonson J. H., Ryan L. M., Blum R. H., Brooks J. S. J., Shiraki M., Frytak S., Parkinson D. R., Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. Journal of Clinical Oncology 1993 11 7 1269 1275 2-s2.0-0027256397 (Pubitemid 23199129)
13. Le Cesne A., Blay J. Y., Judson I., Van Oosterom A., Verweij J., Radford J., Lorigan P., Rodenhuis S., Ray-Coquard I., Bonvalot S., Collin F., Jimeno J., Di Paola E., Van Glabbeke M., Nielsen O. S., Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. Journal of Clinical Oncology 2005 23 3 576 584 2-s2.0-20044372153 10.1200/JCO.2005.01.180 (Pubitemid 46224235)
14. Thornton K. A., Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Core Evidence 2010 4 191 198 2-s2.0-79952220842
15. Scanlan M. J., Simpson A. J., Old L. J., The cancer/testis genes: review, standardization, and commentary. Cancer Immunity 2004 4, article 1 2-s2.0-1442358801
16. Segal N. H., Blachere N. E., Guevara-Patiño J. A., Gallardo H. F., Shiu H. Y., Viale A., Antonescu C. R., Wolchok J. D., Houghton A. N., Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immunity 2005 5, article 2 2-s2.0-32644435433
17. Jungbluth A. A., Antonescu C. R., Busam K. J., Iversen K., Kolb D., Coplan K., Chen Y. T., Stockert E., Ladanyi M., Old L. J., Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. International Journal of Cancer 2001 94 2 252 256 2-s2.0-0035888172 10.1002/ijc.1451 (Pubitemid 32911421)
18. Lai J. P., Robbins P. F., Raffeld M., Aung P. P., Tsokos M., Rosenberg S. A., Miettinen M. M., Lee C. R., NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Modern Pathology 2012 25 6 854 858 10.1038/modpathol. 2012.31
19. Antonescu C. R., Busam K. J., Iversen K., Kolb D., Coplan K., Spagnoli G. C., Ladanyi M., Old L. J., Jungbluth A. A., MAGE antigen expression in monophasic and biphasic synovial sarcoma. Human Pathology 2002 33 2 225 229 2-s2.0-0036213948 10.1053/hupa.2002.31295 (Pubitemid 34298739)
20. Stockert E., Jäger E., Chen Y. T., Scanlan M. J., Gout I., Karbach J., Arand M., Knuth A., Old L. J., A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. Journal of Experimental Medicine 1998 187 8 1349 1354 2-s2.0-2642673605 10.1084/jem.187.8.1349 (Pubitemid 28189124)
21. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America 2003 100 15 8862 8867 2-s2.0-0041305899 10.1073/pnas.1133324100 (Pubitemid 36899189)
22. Jäger E., Nagata Y., Gnjatic S., Wada H., Stockert E., Karbach J., Dunbar P. R., Lee S. Y., Jungbluth A., Jäger D., Arand M., Ritter G., Cerundolo V., Dupont B., Chen Y. T., Old L. J., Knuth A., Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proceedings of the National Academy of Sciences of the United States of America 2000 97 9 4760 4765 2-s2.0-0038691976 10.1073/pnas.97.9.4760 (Pubitemid 30238631)
23. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
24. Weber J. S., Hamid O., Chasalow S. D., Wu D. Y., Parker S. M., Galbraith S., Gnjatic S., Berman D., Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. Journal of Immunotherapy 2012 35 1 89 97
25. + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America 2011 108 40 16723 16728 10.1073/pnas.1110814108
26. Robbins P. F., Morgan R. A., Feldman S. A., Yang J. C., Sherry R. M., Dudley M. E., Wunderlich J. R., Nahvi A. V., Helman L. J., Mackall C. L., Kammula U. S., Hughes M. S., Restifo N. P., Raffeld M., Richard Lee C. C., Levy C. L., Li Y. F., El-Gamil M., Schwarz S. L., aurencot C., Rosenberg S. A., Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology 2011 29 7 917 924
27. Topalian S. L., Hodi F. S., Brahmer J. R., Gettinger S. N., Smith D. C., McDermott D. F., Powderly J. D., Carvajal R. D., Sosman J. A., Atkins M. B., Leming P. D., Spigel D. R., Antonia S. J., Horn L., Drake C. G., Pardoll D. M., Chen L., Sharfman W. H., Anders R. A., Taube J. M., McMiller T. L., Xu H., Korman A. J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G. D., Gupta A., Wigginton J. M., Sznol M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012 366 26 2443 2454
28. Simon R., Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989 10 1 1 10 2-s2.0-0024536437 (Pubitemid 19099520)
29. Robert C., Thomas L., Bondarenko I., 'Day S O., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller Jr W. H., GasconP, Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously unreated metastatic melanoma. The New England Journal of Medicine 2011 364 2517 2526
30. Rosenberg S. A., Cell transfer immunotherapy for metastatic solid cancer- what clinicians need to know. Nature Reviews Clinical Oncology 2011 8 577 585
31. Sato Y., Nabeta Y., Tsukahara T., Hirohashi Y., Syunsui R., Maeda A., Sahara H., Ikeda H., Torigoe T., Ichimiya S., Wada T., Yamashita T., Hiraga H., Kawai A., Ishii T., Araki N., Myoui A., Matsumoto S., Umeda T., Ishii S., Kawaguchi S., Sato N., Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24+ patients with synovial sarcoma. Journal of Immunology 2002 169 3 1611 1618 2-s2.0-0036681961 (Pubitemid 34809210)
32. Kawaguchi S., Wada T., Ida K., Sato Y., Nagoya S., Tsukahara T., Kimura S., Sahara H., Ikeda H., Shimozawa K., Asanuma H., Torigoe T., Hiraga H., Ishii T., Tatezaki S. I., Sato N., Yamashita T., Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. Journal of Translational Medicine 2005 3, article 1 2-s2.0-18044375060 10.1186/1479-5876-3- 1 (Pubitemid 40617864)
33. Tsukahara T., Kawaguchi S., Torigoe T., Kimura S., Murase M., Ichimiya S., Wada T., Kaya M., Nagoya S., Ishii T., Tatezaki S. I., Yamashita T., Sato N., Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Science 2008 99 2 368 375 2-s2.0-38949215429 10.1111/j.1349-7006.2008.00695.x (Pubitemid 351228494)
34. Tsukahara T., Kawaguchi S., Torigoe T., Takahashi A., Murase M., Kano M., Wada T., Kaya M., Nagoya S., Yamashita T., Sato N., HLA-A0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor. Journal of Translational Medicine 2009 7, article 44 2-s2.0-67650097225 10.1186/1479-5876-7-44
35. Kawaguchi S., Wada T., Nagoya S., Sato Y., Ida K., Torigoe T., Sato N., Ishii T., Tatezaki S., Yamashita: T., Phase I vaccination trial of SYT-SSX junction peptide and its JLA-2402 anchor substitute in patients with disseminated synovial sarcoma. Proceedings of the Connective Tissue Oncology Society (CTOS '05) 2005. Abstract 364
36. Kawaguchi S., Wada T., Nagoya S., Tsukahara T., Ida K., Murase M., Torigoe T., Sato N., Yamashita T., The second vaccination tril of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. Proceedings of the Connective Tissue Oncology Society (CTOS '07) 2007. Abstract 817
37. Lee S. Y., Obata Y., Yoshida M., Stockert E., Williamson B., Jungbluth A. A., Chen Y. T., Old L. J., Scanlan M. J., Immunomic analysis of human sarcoma. Proceedings of the National Academy of Sciences of the United States of America 2003 100 5 2651 2656 2-s2.0-0344838426 10.1073/pnas.0437972100 (Pubitemid 36297553)
38. Ayyoub M., Taub R. N., Keohan M. L., Hesdorffer M., Metthez G., Memeo L., Mansukhani M., Hibshoosh H., Hesdorffer C. S., Valmori D., The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immunity 2004 4, article 7 2-s2.0-13444310785
39. Wolchok J. D., Hoos A., O'Day S., Weber J. S., Hamid O., Lebbé C., Maio M., Binder M., Bohnsack O., Nichol G., Humphrey R., Hodi F. S., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research 2009 15 23 7412 7420 2-s2.0-73149092567 10.1158/1078-0432.CCR-09-1624
40. van der Graaf W. T., Blay J. Y., Chawla S. P., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2012 379 9829 1879 1886